Aetna considers transrectal ultrasound (TRUS) medically necessary for any of the specific conditions involving the prostate, rectum and surrounding tissues listed below:
A suspicion of prostatic disease documented by any of the following:
Abnormal digital rectal examination; or
Elevation of prostate-specific antigen (PSA greater than 10 ng/ml); or
Member's history; or
Assessment of anal sphincter dysfunction; or
Clinical staging of a member with prostate cancer; or
Clinical staging of a member with rectal carcinoma; or
Determining volume of the prostate prior to brachytherapy; or
Evaluation of anal and/or rectal fistula; or
Evaluation of anal and/or rectal peri-rectal abscesses; or
Evaluation of hematospermia (hemospermia), to distinguish idiopathic from secondary causes; or
Evaluation of malignant or benign peri-rectal tumors; or
Evaluation of members who have had definitive treatment for carcinoma of the rectum where recurrent disease is noted; or
Infertility and azoospermia where an ejaculatory duct cyst is suspected. (Note: Some benefit plans exclude coverage of infertility services. Please check benefit plan descriptions for details); or
Metastatic lesions of unknown source, with a high PSA level (PSA greater than 10 ng/ml), which could have their origin in the prostate.
Aetna considers TRUS experimental and investigational as a screening test for prostate disease and for all other indications because peer-reviewed medical literature does not support its use for these indications.
Aetna considers TRUS elastography (sono-elastography) experimental and investigational for the evaluation of prostate cancer because its effectiveness has not been established.
Prostate cancer is the most common cause of cancer and the second most common cause of cancer deaths in men in the United States. Prostatic carcinoma generally is slowly progressive and may cause no symptoms. Approximately 50 % of patients with carcinoma of the prostate have either advanced local disease or metastases at the time of diagnosis. This emphasizes the need to detect those patients with potentially curable carcinoma of the prostate at a localized pathologic state. With the development of prostatic ultrasonographic technology, urologists have gained a tool that allows better visualization, more accurate biopsy and earlier detection of carcinoma of the prostate.
Carcinoma of the prostate should be suspected on the basis of abnormal digital rectal findings, hypoechoic lesions on transrectal ultrasound (TRUS), or elevated levels of prostate-specific antigen (PSA). However, diagnosis requires histologic confirmation, most commonly by TRUS-guided transrectal needle biopsy, which can be done without anesthesia. The advent of TRUS-guided biopsies of the prostate, as opposed to blind finger-guided biopsies, has increased the detection rate of prostate cancer when performed in the presence of an abnormal digital rectal examination (DRE) or with an elevation of PSA above 10 ng/ml.
Among several treatment options available, transperineal prostate brachytherapy has evolved as a medically successful, cost-effective outpatient procedure for treating localized prostate cancer. Transperineal prostate brachytherapy utilizes TRUS as the primary imaging procedure to accurately plan and execute the placement of radioactive seeds into the prostate.
There is insufficient information in the published medical literature to support the use of TRUS alone as a screening tool for prostate cancer; however, TRUS can reduce the number of missed cancers in patients with signs or symptoms that may be related to prostate cancer.
In the pre-operative staging of rectal cancer, TRUS is the most accurate imaging modality. It is possible to evaluate the layers of the rectal wall, the depth of tumor penetration and the peri-rectal lymph nodes. TRUS is 85 to 95 % accurate in determining bowel wall penetration and 70 to 80 % accurate in identifying lymph node involvement. The accuracy of the findings, as with all ultrasound examinations, depends on the operator.
Obstructive azoospermia represents approximately 10 % of male hypofertility cases. Cystic lesions of the prostate involving the ejaculatory duct are uncommon in healthy, fertile men; their prevalence increases in infertile men whose examination and semen analyses make them “at risk” for having ductal obstruction. TRUS accurately visualizes abnormalities of the caudal junction of the vas deferens and seminal vesicles, providing a definitive diagnosis without scrototomy.
Transrectal ultrasound is a useful clinical tool for specific conditions involving the prostate, rectum and surrounding tissues. It is less expensive than computed tomography (CT) or magnetic resonance imaging (MRI); the equipment is more mobile, and the procedure can be performed more quickly. Finally, TRUS is well-tolerated by patients, and involves no radiation exposure.
Transrectal ultrasound is the imaging procedure of choice for patients with hematospermia. Polito et al (2006) stated that the presence of blood in ejaculate represents 1 % of all andrological and urological symptoms. In most cases it has a benign character and tends to regress spontaneously after the first episode. But in the same case it can be caused by bladder-prostate or systemic malignant pathology, so it is necessary to subject the patient to laboratory and instrumental tests in order to find the best treatment that, as for hematospermia, is an etiological one. Most important for correct diagnosis are patient history, physical examination, laboratory tests, TRUS examination of the prostate, MRI, CT, cystoscopy. Hematospermia is rarely associated with significant pathology, especially in younger men. The three factors that dictate the extent of the evaluation and treatment are age of patient, the duration and recurrence of the hematospermia, and the presence of any associated hematuria. Thus, it is possible to distinguish idiopathic from secondary hematospermia, because secondary hematospermia, namely, the one in which the bleeding cause is known or suspected, requires an etiologic treatment. Understanding the pathophysiology and prevalence in populations of different ages helps minimize the likelihood of problems. When in doubt, performing a TRUS, cystoscopy, and basic laboratory analyses limits exposure. Also, Zhang et al (2003) reported that TRUS-guided transperineal aspiration of seminal vesicle fluid was helpful to the etiologic diagnosis of persistent hematospermia. Furthermore, Yagci et al (2004) noted that TRUS is a safe, non-invasive method for examining causes of hematospermia. These researchers believed that it should be the first radiological investigation to be performed in patients presenting with hematospermia.
Tissue elasticity has been employed as a qualitative biomarker for prostate cancer and sono-elastography is an emerging imaging tool for providing qualitative as well as quantitative measurements of prostate tissue stiffness. Hoyt and associates (2008) reported that elasticity images obtained with quantitative sono-elastography agree with mechanical testing and histological results. They stated that sono-elastography is a promising biomarker for prostate cancer.
Although elastography is a pormising method, prospective studies are needed to define its applications. Janssen (2008) stated that (endo)sonographic real-time elastography is a new method to describe the mechanical properties of tissue. Similar to color-flow Doppler ultrasonography, a region of interest is defined. The relative stiffness of the tissues within this area is described by colors superimposing on the B-mode image. Real-time elastography can be performed with linear scanners for transcutaneous use, rigid endocavitary probes and with flexible echoendoscopes. The probes can be used to compress the tissue. The elasticity modulus is calculated from the resulting deformation of the tissue. In endoscopic ultrasound, arterial and cardiac pulsations or respiratory movements cause the deformation of the tissue that is used for the calculation. The author concluded that (endo)sonographic real-time elastography is a promising new method. Nevertheless, prospective studies are needed to define useful applications and the clinical significance of the method.
There is emerging evidence to suggest that elastography has the potential to increase ultrasound-based prostate cancer detection. Salomon et al (2008) noted that conventional gray scale ultrasound has a low sensitivity and specificity for prostate cancer detection. These researchers determined sensitivity and specificity for prostate cancer detection with ultrasound-based real-time elastography in patients scheduled for radical prostatectomy (RP). A total of 109 patients with biopsy-proven localized prostate cancer (PCa) underwent elastography before RP. The investigator was blinded to clinical data. A EUB-6500HV ultrasound system with a V53W 7.5 MHz end-fire transrectal probe was used pre-operatively. Areas found to be suspicious for PCa were recorded for left and right side of the apex, mid-gland, and base. These findings were correlated with the obtained whole-mount sections after RP. Sensitivity and specificity for detecting PCa were 75.4 % and 76.6 %, respectively. A total of 439 suspicious areas in elastography were recorded, and 451 cancerous areas were found in the RP specimens. Positive predictive value, negative predictive value, and accuracy for elastography were 87.8 %, 59 %, and 76 %, respectively. Nevertheless, there are limitations to these findings because these researchers investigated specific patients scheduled for RP with apparent PCa. Whether elastography is practical as a diagnostic tool or can be used to target a biopsy and be at least as sensitive in tumor detection as extended biopsy schemes has yet to be determined. The authors concluded that elastography can detect prostate cancer foci within the prostate with good accuracy and has potential to increase ultrasound-based PCa detection. They stated that further studies are needed to validate these data and to assess if tumor detection can be increased by elastography-guided biopsies.
However, there is other evidence to suggest that elastography does not improve cancer detection rates. Eggert and colleagues (2008) found that elastography-guided prostate biopsies did not improve cancer detection in men with suspected prostate cancer. A total of 351 prospectively randomized patients underwent prostate biopsies for the first time. The indication for biopsy was abnormal DRE in 25 % or suspicious PSA elevation in 75 %. In the elastography group (n = 189) and the control group (n = 162), these researchers assessed PSA, DRE, and B-mode TRUS. Both groups underwent classic TRUS-guided 10-core biopsy. Patients in the elastography group underwent additional elastographic examination prior to biopsy using a Voluson 730 ultrasound system. According to the ultrasound or elastographic findings for each biopsy location, the researcher tried to predict whether cancer was present. This prediction was correlated with histopathological findings. The statistical power of this study was sufficient to detect a 15 % difference in detection rate. The study groups did not differ in PSA, clinical stages, or prostate volume (p < 0.05). The overall cancer detection rate was 39 % (137/351): 40.2 % (76/189) in the elastography group and 37.7 % (61/189) in the control group, respectively. The difference in detection rate in clinical stages T2 and T3 between the elastography and the control groups was not statistically significant (p < 0.05). Within the T1c subgroup, elastography showed a slightly higher detection rate of 55.6 % versus 50 % without reaching statistical significance (p > 0.05). Histopathological findings were adequately predicted by elastography in only 44.5 %. The authors concluded that elastography did not improve the cancer detection rate in this cohort of patients.
In a review on the value of real-time elastography in the diagnosis of prostate cancer, Salomon et al (2009) stated that randomized biopsy sampling under TRUS guidance is the gold standard for the diagnosis of prostate cancer. In addition, improvements in the quality of conventional ultrasound, new methods that complement conventional TRUS are opening the door to earlier and better targeted diagnosis of prostate cancer. One of these new methods is sono-elastography. However, its impact on prostate cancer diagnostics has not yet been fully investigated.
Elastography is among a number of new technologies under development for improvement in prostate cancer detection. Trabulsi et al (2010) stated that standard grayscale TRUS has a poor sensitivity for detection of prostate cancer. Saturation biopsy schemes have improved prostate cancer detection rates over standard template biopsy schemes, but carry additional morbidity and cost. Enhanced ultrasound modalities (EUM), including color and power Doppler, contrast-enhancement, harmonic and flash replenishment imaging, as well as elastography have the potential to improve prostate cancer detection. Enhanced ultrasound modalities targeting areas with increased or abnormal vascularity or firmness for biopsy offer improved prostate cancer detection. These new approaches detect prostate cancer more efficiently than standard ultrasound guided biopsies. The authors concluded that these emerging technologies may potentially augment standard prostate biopsy in clinical practice.
Eggert et al (2010) noted that previous studies investigated the clinical impact of elastography for pre-operative staging and as an additional imaging modality to improve prostate cancer detection during prostate biopsy. This rapidly improving technique has facilitated progress toward feasibility and reproducibility of transrectal elastography. Recent studies show significant improvements using the latest generation of elastographic devices. Moreover, the authors stated that further studies are needed to evaluate on the one hand elastography-guided prostate biopsy schemes and results of saturation biopsies; and on the other hand to compare sensitivity and specificity of elastographic detection of prostate cancer with different imaging techniques, especially MRI and spectroscopy.
Aboumarzouk et al (2012) synthesized published data of transrectal elastosonography (TRES) using diagnostic review methodology. Transrectal elastosonography increases prostate cancer detection as compared with grey-scale US. Also, the study highlighted limitations and strengths of data in this area and included recommendations for future research. Two reviewers independently extracted the data from each study. Quality was assessed with a validated quality assessment tool for diagnostic accuracy studies. Diagnostic accuracy of TRES in relation to current standard references (TRUS biopsies and histopathology of RP specimens) was estimated. A bi-variate random effects model was used to obtain sensitivity and specificity values. Hierarchical summary receiver operating characteristic (HSROC) were calculated. In all, 16 studies (2,278 patients) were included in the review. Using histopathology of the RP specimen as reference standard, the pooled data of 4 studies showed that the sensitivity of TRES ranged between 0.71 to 0.82 and the specificity ranged between 0.60 to 0.95 (pooled diagnostic odds ratio [DOR] 19.6; 95 % confidence interval [CI]: 7.7 to 50.03). The sensitivity varied from 0.26 to 0.87 and specificity varied from 0.17 to 0.76 (pooled DOR 2.141; 95 % CI: 0.525 to -8.737) using TRUS biopsies (minimum of 10) as a reference standard. The quality of most studies was modest. SROC estimated 0.8653 area under the curve predicting high chances of detecting prostate cancer. There were no health economics or health-related quality of life of the participants reported in the studies and all the studies used compressional technique with no reported standardisation. The TRES technique appears to improve the detection of prostate cancer compared with systematic biopsy and shows a good accuracy in comparison with histopathology of the RP specimen. However, the authors noted that studies lacked standardization of the technique, had poor quality of reporting and a large variation in the outcomes based on the reference standards and techniques used.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
Other CPT codes related to the CPB:
77326 - 77328
77761 - 77778, 77789
ICD-9 codes covered if selection criteria are met:
154.0 - 154.8
Malignant neoplasm of the rectum, rectosigmoid junction, and anus
Malignant neoplasm of prostate
Malignant neoplasm of pelvis
Secondary malignant neoplasm of large intestine and rectum
Secondary malignant neoplasm of genital organs
Benign neoplasm of rectum and anal canal
Benign neoplasm of prostate
Carcinoma in situ of rectum
Carcinoma in situ of anal canal
Carcinoma in situ of anus, unspecified
Carcinoma in situ of prostate
Neoplasm of uncertain behavior of stomach, intestines, and rectum
Neoplasm of uncertain behavior of prostate
Abscess of anal and rectal regions
Other specified disorders of rectum and anus (to be used for anal sphincter dysfunction)
606.0 - 606.9
Elevated prostate specific antigen
Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus
Personal history of malignant neoplasm of prostate
ICD-9 codes not covered for indications listed in the CPB:
Observation for suspected malignant neoplasm
Special screening for malignant neoplasms of rectum
Special screening for malignant neoplasms of prostate
The above policy is based on the following references:
Selley S, Donovan J, Faulkner A, et al. Diagnosis, management and screening of early localised prostate cancer. Health Tech Assess. 1997;1(2):i, 1-96.
Lee F, Bahn DK, Siders DB, et al. The role of TRUS-guided biopsies for determination of internal and external spread of prostate cancer. Semin Urol Oncol. 1998;16(3):129-136.
Aarnink RG, Beerlage HP, De La Rosette JJ, et al. Transrectal ultrasound of the prostate: Innovations and future applications. J Urol. 1998;159(5):1568-1579.
Clements R. Has ultrasonography a role in screening for prostatic cancer? Eur Radiol. 1997;7(2):217-223.
Smith JA Jr. Transrectal ultrasonography for the detection and staging of carcinoma of the prostate. J Clin Ultrasound. 1996;24(8):455-461.
Anderson JE. Prostatic imaging: The role of transrectal ultrasound. Aust Fam Physician. 1995;24(4):557-558, 560-561.
Lee F, Torp-Pedersen ST, Siders DB. Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer. Urology. 1989;33(6 Suppl):7-12.
U.S. Preventive Services Task Force. Screening for prostate cancer. In: Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996:119-134.
Canadian Task Force on the Periodic Health Examination. Screening for prostate cancer. In: Canadian Guide to Preventive Health Care. Ottawa, ON: Canada Communications Group; 1994:812-823.
American Urologic Association (AUA). Early detection of prostate cancer and use of transrectal ultrasound. In: American Urologic Association 1992 Policy Statement Book. Linthicum, MD: AUA; 1992.
Fried RM, Davis NS, Weiss GH. Prostate cancer screening and management. Med Clin N Am. 1997;81(3):801-822.
Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: Defining local versus systemic failure. Semin Urol Oncol. 1999;17(3):130-134.
Deliveliotis C, John V, Louras G, et al. Multiple transrectal ultrasound guided prostatic biopsies: Morbidity and tolerance. Int Urol Nephrol. 1999;31(5):681-686.
Hussain SM, Stoker J, Schutte HE, et al. Imaging of the anorectal region. Eur J Radiol. 1996;22(2):116-122.
Barbaro B, Schulsinger A, Valentini V, et al. The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 1999;43(5):1043-1047.
Kim SH, Paick JS, Lee IH, et al. Ejaculatory duct obstruction: TRUS-guided opacification of seminal tracts. Eur Urol. 1998;34(1):57-62.
Kime ED, Onel E, Honig SC, et al. The prevalence of cystic abnormalities of the prostate involving the ejaculatory ducts as detected by transrectal ultrasound. Int Urol Nephrol. 1997;29(6):647-652.
Cornud F, Belin X, Delafontaine D, et al. Imaging of obstructive azoospermia. Eur Radiol. 1997;7(7):1079-1085.
Jarow JP. Role of ultrasonography in the evaluation of the infertile male. Semin Urol. 1994;12(4):274-282.
Hellerstein DK, Meacham RB, Lipshultz LI. Transrectal ultrasound and partial ejaculatory duct obstruction in male infertility. Urology. 1992;39(5):449-452.
Wallner K, Ellis W, Russell K, et al. Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43(3):583-585.
Badiozamani KR, Wallner K, Cavanagh W, et al. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys. 1999;43(2):375-378.
Pathak SD, Grimm PD, Chalana V, et al. Pubic arch detection in transrectal ultrasound guided prostate cancer therapy. IEEE Trans Med Imaging. 1998;17(5):762-771.
Lee SH. Case report: Transrectal ultrasound in the diagnosis of ano-rectal varices. Clin Radiol. 1994;49(1):69-70.
DeVita VT Jr., Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven;1997:1198.
Pidala MJ, Oliver GC. Local treatment of rectal cancer. Am Fam Physician. 1997;56(6):1622-1628.
Flesman JW, Myerson RJ, Fry RD, et al. Accuracy of transrectal ultrasound in predicting pathologic stage of rectal cancer before and after preoperative radiation therapy. Dis Colon Rectum. 1992;35(9):823-829.
Vignati PV, Roberts PL. Preoperative evaluation and postoperative surveillance for patients with colorectal carcinoma. Surg Clin N Amer. 1993;73(1):67-84.
Senagore AJ. Intrarectal and intraanal ultrasonography in the evaluation of colorectal pathology. Surg Clin N Amer. 1994;74:1465-1473.
Murray JJ, Stahl TJ. Sphincter-saving alternative for treatment of adenocarcinoma involving distal rectum. Surg Clin N Amer. 1993;73(1): 131-144.
Hulsmans FJ, Tio TL, Fockens P, et al. Assessment of tumor infiltration depth in rectal cancer with transrectal sonography: Caution is necessary. Radiol. 1994;190(3):715-720.
Heneghan JP, Salem RR, Lange RC, et al. Transrectal sonography in staging rectal carcinoma: The role of gray-scale, color-flow, and Doppler imaging analysis. Am J Roentgenol. 1997;169(5):1247-1252.
Littrup PJ, Bailey SE. Prostate cancer: The role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am. 2000;38(1):87-113.
Applewhite JC, Matlaga BR, McCullough DL, et al. Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control. 2001;8(2):141-150.
Scherr DS, Eastham J, Ohori M, et al. Prostate biopsy techniques and indications: When, where, and how? Semin Urol Oncol. 2002;20(1):18-31.
Goossen T, Wijkstra H. Transrectal ultrasound imaging and prostate cancer. Arch Ital Urol Androl. 2003;75(1):68-74.
Hittelman AB, Purohit RS, Kane CJ. Update of staging and risk assessment for prostate cancer patients. Curr Opin Urol. 2004;14(3):163-170.
Song JM, Kim CB, Chung HC, Kane RL. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: A meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men. Yonsei Med J. 2005;46(3):414-424.
Zhang K, Li, SQ, He ZJ, et al. Etiology and management of persistent hematospermia: A pilot study. Zhonghua Nan Ke Xue. 2003;9(2):118-121.
Yagci C, Kupeli S, Tok C, et al. Efficacy of transrectal ultrasonography in the evaluation of hematospermia. Clin Imaging. 2004;28(4):286-290.
Polito M, Giannubilo W, d'Anzeo G, Muzzonigro G. Hematospermia: Diagnosis and treatment. Arch Ital Urol Androl. 2006;78(2):82-85.
Boczko J, Messing E, Dogra V. Transrectal sonography in prostate evaluation. Radiol Clin North Am. 2006;44(5):679-687, viii.
Ahmad I, Krishna NS. Hemospermia. J Urol. 2007;177(5):1613-1618.
Manohar T, Ganpule A, Desai M. Transrectal ultrasound- and fluoroscopic-assisted transurethral incision of ejaculatory ducts: A problem-solving approach to nonmalignant hematospermia due to ejaculatory duct obstruction. J Endourol. 2008;22(7):1531-1535.
La Vignera S, Calogero AE, Arancio A, et al. Transrectal ultrasonography in infertile patients with persistently elevated bacteriospermia. Asian J Androl. 2008;10(5):731-740.
Hoyt K, Castaneda B, Zhang M, et al. Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomark. 2008;4(4-5):213-225.
Janssen J. (E)US elastography: Current status and perspectives. Z Gastroenterol. 2008;46(6):572-579.
Salomon G, Köllerman J, Thederan I, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: A comparison with step section pathological analysis after radical prostatectomy. Eur Urol. 2008;54(6):1354-1362.
Eggert T, Khaled W, Wenske S, et al. Impact of elastography in clinical diagnosis of prostate cancer. A comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies. Urologe A. 2008;47(9):1212-1217.
Salomon G, Graefen M, Heinzer H, et al. The value of real-time elastography in the diagnosis of prostate cancer. Urologe A. 2009;48(6):628-636.
Eggert T, Brock M, Noldus J, Ermert H. Rising PSA level and negative prostate biopsy. Can prostate elastography help? Urologe A. 2010;49(3):376-380.
Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. Urology. 2010;76(5):1025-1033.
King AC, Livermore A, Laurila TA, et al. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol. 2011 Aug 2. [Epub ahead of print]
Aboumarzouk OM, Ogston S, Huang Z, et al. Diagnostic accuracy of transrectal elastosonography (TRES) imaging for the diagnosis of prostate cancer: A systematic review and meta-analysis. BJU Int. 2012;110(10):1414-1423; discussion 1423
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.